Clinical Trial

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Study acronym: ZODIAC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-01-31; most recent amendment 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2025-04-02
Trial Details
NCT Number NCT06250036
Lead Sponsor Royal Marsden NHS Foundation Trust
Collaborators: Gilead Sciences
Conditions Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
Enrollment 50 participants
Start Date 2025-02-20
Primary Completion 2027-03-20 (estimated)
Study Completion 2031-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-21